Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/07/微信截图_20240709140939.jpg)
Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1%
Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1%
![Gastric Cancer](https://www.medtourcn.com/wp-content/uploads/2024/07/微信截图_20240709140939.jpg)
Gastric Cancer
According to a report by People’s Daily on April 6, 2023, China has achieved another milestone in the CAR-T field. Recently, China Jiangxi Province successfully completed its first case of CAR-T cell therapy for solid tumors. This not only represents a significant breakthrough in new cancer treatment technologies in Jiangxi but also marks a major advancement in China’s CAR-T research and application.
China’s Jiangxi Achieves a Breakthrough in CAR-T Therapy for Solid Tumors
The patient, an advanced gastric cancer patient, had previously undergone chemotherapy combined with immune checkpoint inhibitor (ICI) treatment, but the disease was not well controlled. The tumor had widely metastasized to the abdominal cavity and multiple bones, accompanied by complications such as anorexia, abdominal distension, and severe recurrent reduction in blood cells, making the patient unable to tolerate chemotherapy.
With no other options, the patient received CAR-T cell reinfusion therapy on March 20, 2023, at the Oncology Center of The Second Affiliated Hospital of Nanchang University, with substantial support from the team at Peking University Cancer Hospital (Beijing Cancer Hospital). Fortunately, the patient has safely passed the peak period of cytokine release syndrome (CRS). Compared to before CAR-T treatment, tumor markers have decreased to normal levels, and the patient’s physical condition, mental state, and symptoms (such as abdominal distension and anorexia) have significantly improved. This marks a “zero breakthrough” for CAR-T cell therapy in solid tumors in Jiangxi Province of China, leaving a significant mark in the field of CAR-T research and application in China.
Peking University Cancer Hospital Showcases CT041 CAR-T at 2024 ASCO Conference with a Disease Control Rate of 96.1%
In addition to this fortunate case, the research team from Peking University Cancer Hospital showcased a domestically developed CAR-T product named “satri-cel” (development code CT041) at the recent 2024 American Society of Clinical Oncology (ASCO) conference. Satri-cel is a CAR-T cell therapy targeting Claudin18.2 (CLDN18.2) and is the only CLDN18.2 CAR-T cell therapy in the world approved for clinical trials (IND) in both China and the United States, targeting digestive tract tumors such as gastric cancer and pancreatic cancer.
The final results of the Phase 1 clinical trial (NCT03874897) were presented in an oral report at this conference. In patients with gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) treated with satri-cel monotherapy, the results showed a disease control rate (DCR) of 96.1% (49/51), an objective response rate (ORR) of 54.9% (28/51), a median overall survival (mOS) of 9.0 months, a median progression-free survival (mPFS) of 5.8 months, and a median duration of response (mDOR) of 6.4 months.
As early as May 2022, the team at Peking University Cancer Hospital had reported clinical cases of CT041 treating gastric cancer. A 57-year-old gastric cancer patient (Pt08), who had previously undergone three treatments, including PD-1 antibody, showed improvement after receiving CT041 CAR-T cell therapy. Visual inspection and CT scans indicated that the patient’s condition improved, with reduced umbilical tumor lesions, and the efficacy was still ongoing as of the date of the report.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #GastricCancer #LiverCancer #BrainTumor #PancreaticCancer #MedicalBreakthrough #Oncology #Jiangxi #ChinaBiotech #CancerResearch #ASCO2024 #PekingUniversityCancerHospital #InnovativeTherapy #MedicalAdvancements #HealthNews
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/20240604.png)
Nature Medicine | New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment
Nature Medicine | **New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment**
![Nature Medicine](https://www.medtourcn.com/wp-content/uploads/2024/06/20240604.png)
Nature Medicine
In the medical field, unresectable advanced or metastatic gastric or gastroesophageal junction (#GEJ) adenocarcinoma has always been a daunting challenge. However, the latest research brings new hope to this field. #metastaticgastric #gastroesophagealjunction
**Innovative Treatment Brings New Hope**
The latest study published in *Nature Medicine* indicates that the drug Cadonilimab, in combination with chemotherapy, has significant efficacy and safety for patients with HER2-negative unresectable advanced or metastatic gastric or GEJ adenocarcinoma. This study, jointly conducted by scholars such as Jiafu Ji, Ziyu Li, and Lin Shen from Peking University, brings exciting news to this field.
**Key Findings**
Key findings of the study include:
– Cadonilimab in combination with chemotherapy has significant benefits for tumor response and survival, offering patients a ray of hope.
– The median overall survival reached 17.48 months in all patients, with higher benefits observed in patients with higher PD-L1 expression, reaching a median overall survival of 20.32 months in patients with PD-L1 CPS≥5.
– Even in patients with PD-L1 CPS<1, encouraging survival benefits were observed, with a median overall survival of 17.64 months.
– The drug demonstrated good safety profile, with treatment-related adverse events being manageable and tolerable.
**Dawning of Hope**
This study brings new hope to patients with gastric adenocarcinoma or GEJ adenocarcinoma. Regardless of PD-L1 expression, Cadonilimab in combination with chemotherapy exhibits encouraging clinical activity and manageable safety. This innovative treatment regimen holds the promise of fundamentally changing this life-threatening disease worldwide.
**Conclusion**
This groundbreaking research highlights the leading position of Chinese medical teams in the field of gastric adenocarcinoma treatment. With further research, we hope to see more innovative treatment options emerge, providing patients with more opportunities for survival and better quality of life. Let us look forward to the progress of medical science and bring more hope for health!
Want to know more Advanced medicine in China, You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com
or WhatsApp 137 1795 9070.
The Medical Department will contact you as soon as they receive the reports.
#GastricAdenocarcinomaTreatment #MedicalInnovation #HopeForHealth #gastriccarcinoma #gastriccancer #HER2 #Adenocarcinoma #cancertretment #chinesemedical #medicalscience #hope #hopeforhealth #NatureMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/02/202402140.png)
Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements
🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬
Patient 1: 53-year-old Male
![Gastric Cancer,Pancreatic Cancer](https://www.medtourcn.com/wp-content/uploads/2024/02/202402140.png)
Gastric Cancer,
Pancreatic Cancer
Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by nearly 50%, achieving sustained remission for 32 weeks.
Patient 2: 57-year-old Female
![Gastric Cancer,Pancreatic Cancer](https://www.medtourcn.com/wp-content/uploads/2024/02/202402141.png)
Gastric Cancer,
Pancreatic Cancer
Gastric cancer with peritoneal metastasis and Sister Mary Joseph’s nodule (malignant tumor metastasis forming a nodule-like lesion in the umbilicus). Previously received third-line therapy including PD-1 antibodies, CLDN18.2 expression 80% (2+). Achieved partial remission after CAR-T therapy, with sustained response exceeding 56 weeks.
🏆 CT041 Achievements 🏆
– In May 2020, FDA approved CT041 for investigational new drug (IND) authorization for the treatment of claudin18.2-positive gastric, gastroesophageal junction, or pancreatic adenocarcinoma patients.
– In 2020, received orphan drug designation from the U.S. FDA for the treatment of gastric/gastroesophageal junction cancer.
– In 2021, granted orphan drug designation by the European Medicines Agency (EMA) and qualified for the European PRIME program.
– In 2022, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.
– On March 3, 2022, approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to enter Phase II clinical trials!
We are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!
we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
doctor.huang@globecancer.com,
or WhatsApp+8613717959070
The Medical Department will contact you as soon as they receive the reports.
#CancerResearch #Immunotherapy #CART #MedicalBreakthrough #ClinicalTrials #FDAApproval #OrphanDrug #HealthcareInnovation #GastricCancer #PancreaticCancer #CT041 #MedicalAdvancement #RegenerativeMedicine #RMAT #EMAApproval #NMPAApproval #MedicalScience #PrecisionMedicine #PatientCare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/02/202402130.png)
Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results!
🎉 Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results! 🚀
![Gastric Cancer, Pancreatic Cancer](https://www.medtourcn.com/wp-content/uploads/2024/02/202402130.png)
Gastric Cancer, Pancreatic Cancer
A burgeoning therapeutic target for gastric cancer—Claudin 18.2, its discovery has also opened a new chapter in targeted therapy for gastric cancer. If we talk about the hottest cell immunotherapy in recent years, it has to be chimeric antigen receptor T-cell (CAR-T) therapy. Based on this, Chinese researchers have developed the world’s first CAR-T cell therapy targeting Claudin18.2—CT041.
CT041, as the first CAR-T cell therapy targeting Claudin18.2, made its debut at the 2019 ASCO Annual Meeting. Among 12 patients with metastatic adenocarcinoma (7 gastric cancer, 5 pancreatic cancer) treated with Claudin18.2-targeting CAR T-cell therapy, no severe adverse events, treatment-related deaths, or serious neurotoxicity were reported. Among the 11 evaluated patients: 1 (gastric adenocarcinoma) achieved complete remission; 3 (2 gastric adenocarcinoma, 1 pancreatic adenocarcinoma) achieved partial remission; 5 had stable disease; and 2 experienced disease progression. The overall objective response rate was 33.3%.
At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) held on January 19, 2024, SciGen showcased a clinical study of Claudin18.2-targeting autologous CAR-T cell therapy CT041 (satri-cel), reporting results from the dose escalation phase of the ELIMYN18.2 1b clinical trial conducted in the United States for the treatment of gastric/esophagogastric junction adenocarcinoma (GC/GEJ) or pancreatic cancer (PC).
This single-arm, open-label phase 1b/2 study primarily evaluated the safety and efficacy of CT041 in patients with advanced Claudin18.2-positive gastric/esophagogastric junction adenocarcinoma (GC/GEJ, progressing after at least second-line treatment or intolerant) or pancreatic cancer (PC, progressing after at least first-line treatment or intolerant).
Nineteen patients (9 GC/GEJ patients, 12 PC patients) received CT041 treatment at doses ranging from 250 to 600×106 cells: dose 1: 250-300×106 (n=6), dose 2: 375-400×106 (n=6), dose 3: 600×106 (n=7). All patients had received systemic therapy, with 85.7% of GC/GEJ patients and 58.3% of PC patients receiving ≥3 lines of systemic therapy. The median number of metastatic organs for all patients was 2, with at least one prior infusion. Clinical benefit rate included complete remission [CR], partial remission [PR], and stable disease [SD] ≥180 days.
As of September 15, 2023, with a median follow-up of 8.9 months, across all dose groups, the confirmed objective response rate (ORR) for gastric/esophagogastric junction adenocarcinoma patients was 42.9% (3/7); clinical benefit rate (CBR) was 57.1% (4/7); median progression-free survival (mPFS) and median duration of response (mDOR) were 5.7 months and 6.9 months, respectively. Additionally, the median overall survival (mOS) for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 8.9 months. In dose level 3 (DL3), one gastric/esophagogastric junction adenocarcinoma patient achieved complete remission (CR). The clinical benefit rate for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 71.4% (5/7), with a median OS of 12.9 months.
In summary, #CT041, as the first autologous #Claudin182 CAR-T cell therapy, demonstrates encouraging safety and shows promising preliminary efficacy in Claudin18.2-positive advanced GC/GEJ and PC patients who have received multiple prior treatments.
You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com, or click on the WhatsApp+8613717959070 icon on the homepage. The Medical Department will contact you as soon as they receive the reports.
🌟 #CART #Immunotherapy #CT041 #CancerResearch #ClinicalTrials #GastricCancer #PancreaticCancer #SciGen #ASCOGI2024